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Genomic assays for Epstein–Barr virus-positive
gastric adenocarcinoma
Margaret L Gulley
A small set of gastric adenocarcinomas (9%) harbor Epstein–Barr virus (EBV) DNA within malignant cells, and the virus is not an
innocent bystander but rather is intimately linked to pathogenesis and tumor maintenance. Evidence comes from unique
genomic features of host DNA, mRNA, microRNA and CpG methylation profiles as revealed by recent comprehensive genomic
analysis by The Cancer Genome Atlas Network. Their data show that gastric cancer is not one disease but rather comprises four
major classes: EBV-positive, microsatellite instability (MSI), genomically stable and chromosome instability. The EBV-positive
class has even more marked CpG methylation than does the MSI class, and viral cancers have a unique pattern of methylation
linked to the downregulation of CDKN2A (p16) but not MLH1. EBV-positive cancers often have mutated PIK3CA and ARID1A
and an amplified 9p24.1 locus linked to overexpression of JAK2, CD274 (PD-L1) and PDCD1LG2 (PD-L2). Multiple noncoding
viral RNAs are highly expressed. Patients who fail standard therapy may qualify for enrollment in clinical trials targeting cancer-
related human gene pathways or promoting destruction of infected cells through lytic induction of EBV genes. Genomic tests
such as the GastroGenus Gastric Cancer Classifier are available to identify actionable variants in formalin-fixed cancer tissue of
affected patients.
Experimental & Molecular Medicine (2015) 47, e134; doi:10.1038/emm.2014.93; published online 23 January 2015
INTRODUCTION
Epstein–Barr virus (EBV) is present within the malignant cells
in ~ 9% of all gastric adenocarcinomas worldwide.1 Another
pathogen, Helicobacter pylori (Hp), commonly present in the
stomach, confers a fivefold increased cancer risk.2 Gastric
cancer is the leading cause of infection-related cancer mortality
and is projected to soon rise to rank eighth in all-cause
mortality.3,4 By the time gastric cancer is diagnosed, a billion
or more malignant cells are typically present harboring
dozens to thousands of somatic gene variants. Genomic tests
show promise to identify driver mutations such as ERBB2
amplification for which targeted therapy may be effective.5
Understanding the functional impact of genomic variation
promotes selection of drugs that target relevant pathways and
thus could overcome unwanted effects that promote growth,
thwart apoptosis, elude the immune system or impair DNA
repair mechanisms that foster more mutagenesis.6–9
Enrollment in clinical trials of targeted therapy
increasingly relies on results of tests for pertinent genes and
gene products. This article describes the current state of
genomic assay development for gastric cancer and the
opportunities to capitalize on EBV and its effectors as targets
for therapy.
FOUR MAJOR MOLECULAR CLASSES OF GASTRIC
ADENOCARCINOMA
Data from The Cancer Genome Atlas (TCGA) Network suggest
that gastric adenocarcinoma is not one disease but rather
comprises four molecular classes, as discovered by comprehen-
sive tests of 295 frozen gastric cancer tissues from untreated
patients using whole exome sequencing, RNAseq, microRNA
sequencing, SNP array, methylation array, reverse-phase protein
array, microsatellite instability (MSI) testing and (in 107 tumors)
whole genome sequencing.10 Matched germline DNA (generally
from blood) and non-malignant gastric mucosa were also
examined. The summary of key findings is provided in Table 1.
MICRORNA AND MESSENGER RNA PROFILES IN
EBV-POSITIVE GASTRIC ADENOCARCINOMA
EBV was the first virus recognized to encode its own micro-
RNAs. MicroRNA and mRNA profiles are achievable in
formalin-fixed, paraffin-embedded tissue using massively
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parallel sequencing or array technology. The summary of RNAs
distinguishing each of the four cancer classes from non-
malignant gastric mucosa is provided in Table 2.10–18 Several
downregulated mRNAs are shared among the four gastric
cancer classes, implying these RNAs are pancancer markers in
the stomach. Conversely, CST1 is upregulated in all four cancer
classes.
EBV-ASSOCIATED DNA HYPERMETHYLATION
A striking feature of EBV-positive gastric cancer is extreme
CpG hypermethylation, including both promoter and non-
promoter CpG islands of the human genome.10,19,20 Notably,
the pattern of methylation is even more extensive than the
classic CpG island methylator phenotype observed in the MSI
class of gastric cancers, and is more extensive than was seen
in any tumor type previously studied by the TCGA
Network.10,21,22 Furthermore, EBV and MSI methylation
patterns are distinct, with EBV-positive tumors displaying
CDKN2A (p16) promoter hypermethylation but lacking MLH1
hypermethylation.10,23,24
The genes silenced in virtually all EBV-positive cancers in
concert with promoter hypermethylation are listed in Table 3.10
The RCOR2 gene exhibited methylation-related silencing in
100% of EBV-positive and in 0% of EBV-negative gastric
cancers. Work on cell lines suggests that downregulation of the
RCOR2 transcription factor promotes hypermethylation,
whereas expression of RCOR2 promotes reprogramming to
stem cell pluripotency.25,26
EBV infection leads to extensive methylation of both host
and viral genomes, providing a mechanism for viral control
of cellular functions promoting viral persistence and
propagation.20,27–32 EBV BZLF1 was the first protein ever
shown to preferentially bind methylated promoters to induce
gene expression, thus overcoming transcriptional silencing to
switch an infected cell from viral latency to active, lytic viral
replication. Interestingly, Hp infection is also associated with
hypermethylation.33 In vitro evidence points to demethylating
drugs that can reverse the effect, but clinical trials of
EBV-positive tumors (lymphoma and nasopharyngeal carci-
noma) treated with 5-azacytidine plus phenylbutyrate had
disappointing results.34
EBV-DIRECTED THERAPY, AND GENOMIC TESTS TO
MONITOR EFFICACY
As viral DNA and selected viral gene products (see below) are
present in every malignant cell of an EBV-positive tumor, a
compelling cure for cancer would be to eliminate all infected
cells. Strategies for virus-directed therapy are listed in Table 4.
Lytic induction therapy is a rational means to promote
destruction of infected cells, and the putative mechanisms of
action were recently summarized by Kenney and Mertz.35
Radiation therapy and selected drugs induce lytic viral gene
expression, enhancing immune recognition of foreign
proteins.35–37 Radiation is effective in treating some EBV-
infected cancers such as nasopharyngeal carcinoma and
Hodgkin’s lymphoma. Histone deacetylase inhibitors are
among the most potent inducers of active viral replication.38
Short-chain fatty acids such as butyrate are also good inducers
having reasonable safety profiles. Butyrate is produced naturally
by certain bacteria comprising the oral and gastric flora.39
Nucleoside analog drugs such as gancyclovir may enhance cell
death during lytic induction therapy35 (see Figure 1). Two
clinical trials reported positive biologic effects and minimal
toxicity.40,41
Table 1 Key genomic characteristics in the four molecular classes of gastric adenocarcinoma proposed by The Cancer Genome
Analysis Network
Epstein–Barr virus positive (9% of gastric cancers)
PIK3CA mutation
Marked DNA hypermethylation including in CDKN2A (p16) but not MLH1 promoters
JAK2 gene amplification
Immune response gene dysregulation with CD274 and PDCD1LG2 (PD-L1 and PD-L2) amplification and overexpression
Microsatellite instability (22% of gastric cancers)
Extensive DNA hypermethylation with epigenetic silencing of MLH1
Hypermutation of many genes including HLA class 1 factors affecting antigen presentation
Genomically stable (20% of gastric cancers)
Unique GTPase-activating mutations or fusions (RHOA or ARHGAPs)
CDH1 (E-cadherin) mutation (somatic)
Diffuse histologic subtype
Chromosome instability (50% of gastric cancers)
Multiple gene amplifications and deletions—notably EGFR, VEGFA and other receptor tyrosine kinase gene amplification, or cell cycle regulatory gene
amplification (CCND1, CCNE1, CDK6)
TP53 mutation
Abbreviation: HLA, human leukocyte antigen.
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A major aim of the lytic induction therapy is to provoke host
cell expression of immunogenic foreign proteins that incite
immune responses. Decades of experience treating EBV-driven
posttransplant lymphoproliferation shows that cutting back on
iatrogenic-immunosuppressive drugs restores the body’s
natural ability to control EBV infection, potentially reducing
tumor burden as reflected by lower viral load in the plasma.42
In solid tumor patients, EBV-directed T cells infused in
concert with immune modulators have some efficacy against
infected cancers.43 Drugs that were ineffective as single agents
are now being considered in combination, such as a histone
deacetylase inhibitor (e.g. vorinostat, suberoylanilide hydro-
xamic acid or valproate) plus the proteasome inhibitor
bortezomib.35,44–49 Triple drug therapy with gancyclovir plus
gemcitabine and valproate (both of which induce lytic viral
replication) showed anecdotal value in stabilizing three naso-
pharyngeal carcinoma patients.41 Clinical trials should report
EBV status as well as pertinent genomic features to characterize
exceptional responders and to shed light on mechanisms of
action in relevant biochemical pathways.
Laboratory tests can measure the degree of lytic induction
using quantitative PCR to quantify viral genomes and tran-
scriptome profiles to measure lytic mRNAs. Parallel tests of
human RNA evaluate the impact on pertinent cellular bio-
chemical pathways. These tests may be applied to biopsy
material, although periodic rebiopsy is impractical and risky.
Plasma is emerging as a more practical specimen type in which
to measure tumor markers (EBV viral load, somatic mutations
and microRNA or methylation profiles) to assess near-term
effects of intervention and long-term tumor burden.50–53
HOST GENE MUTATION
A salient feature of EBV-positive gastric cancer is PIK3CA
mutation, which is found in 80% of such cancers compared
with only 3–42% for cancers in the other three molecular classes.
Interestingly, nearly half of EBV-positive nasopharyngeal carci-
nomas harbor PIK3CA mutation, implicating a common theme
to viral carcinogenesis despite squamous vs glandular histologies.
This is a classic example of genomic features linking two cancer
types despite different histologies and anatomic sites.54
In EBV-positive gastric cancer, PIK3CA mutations are not
restricted to hotspots (helical or kinase domains) but rather are
spread across many gene segments.10 Clinical trials of various
PIK3CA/AKT/mTOR inhibitors (e.g. everolimus, BEZ235)
showed disappointing results as single agents in gastric cancer,
and dual pathway inhibition is now being explored.55–60
Unique cancer prevention strategies are also being explored
for PIK3CA-mutated cancers.
Human genes commonly mutated in gastric cancer are listed
in Table 5.10 The vast majority of cancers have mutation or
Table 2 Top 10 most dysregulated human mRNAs and microRNAs in gastric cancer tissue compared with non-malignant
mucosaa
EBV+ MSI Genomically stable Chromosome instability
Upregulated Downregulated Upregulated Downregulated Upregulated Downregulated Upregulated Downregulated
CST1 GKN1 CST1 GKN1 SFRP4 GKN1 CST1 GKN1
CXCL9 GKN2 CLDN3 GKN2 CLDN3 GKN2 CLDN3 GKN2
CXCL10 REG3A CDH17 PGC THBS4 LIPF VIL1 LIPF
CXCL11 TFF1 SPP1 LIPF THBS2 PGC SFRP4 GIF
UBD LIPF COL10A1 REG3A CST1 TFF2 CLDN1 PGA3
IDO1 TFF2 IL8 GIF BGN GIF CDH17 REG3A
MMP7 PSCA CXCL1 PGA3 FNDC1 REG3A MUC3A CHGA
CLDN1 PGC SULF1 CHGA COL8A1 PGA3 MMP11 IGJ
APOC1 GIF CXCL9 CXCL17 ASPN PSCA COL10A1 KRT20
OLFM4 PGA3 MMP11 KRT20 SULF1 CXCL17 INHBA PGC
MicroRNAs:
Mir-142 Mir-375 Mir-196b (none were significant) Mir-196a Mir-451 Mir-196a Mir-1
Mir-335 Mir-1 Mir-196a Mir-196b Mir-1 Mir-196b Mir-133a
Mir-146b Mir-133a Mir-210 Mir-217 Mir-486 Mir-135b Mir-145
Mir-21 Mir-9 Mir-194-2 Mir-21 Mir-144 Mir-194-2 Mir-145
Mir-501 Mir-145 Mir-429 Mir-708 Mir-9 Mir-192 Mir-139
Mir-146b Mir-139 Mir-200a Mir-146b Mir-133a Mir-194 Mir-451
Mir-455 Mir-451 Mir-183 Mir-146b Mir-29c Mir-21 Mir-9
Mir-181a-1 Mir-145 Mir-194 Mir-181a-1 Mir-145 Mir-501 Mir-486
Mir-181b Mir-486 Mir-192 Mir-542 Mir-365 Mir-335 Mir-29c
Mir-19a Mir-29c Mir-182 Mir-199b Mir-139 Mir-183 Mir-143
Abbreviations: EBV, Epstein–Barr virus; MSI, microsatellite instability.
aRanked in order of fold change in mRNA or microRNA level, with highest fold change at the top.
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gene amplification in a targetable signaling pathway (receptor
tyrosine kinases such as MET or EGFR, JAK/STAT, GTPase
(RHO/RAS/RAF), PIK3CA/MTOR/PTEN, CTNNB1). RNAseq
revealed MET exon skipping (of exons 2, 18/19 or 19)
associated with overexpression of the encoded receptor. MET
gene amplification was found in about a third of EBV-positive
cancers.
EBV-positive cancers typically lack TP53 mutation, although
TP53 was nearly always mutated in ‘chromosome instability’
cancers,10 which might be detectable by immunohistochemical
evidence of TP53 protein accumulation.61 Indeed, TP53
immunostains already serve as an adjunct to histopathology
in predicting progression of Barrett’s lesions to cancer.62
Shimizu et al.63 recently reported TP53 or ARID1A mutation
at low allele frequency in non-malignant gastric mucosa of
patients with Hp infection, and Hp-related mutagenesis is
purportedly related to activation of cytidine deaminase leading
to characteristic C4T transversions of GpCpX motifs.
EBV-RELATED IMMUNE SYSTEM DYSFUNCTION
IDENTIFIED IN TCGA STUDIES
Autocrine or paracrine growth factors seem to promote growth
of tumor cells. The TCGA Network reported that, compared
with EBV-negative cancers, EBV-positive cancers have evidence
of hyperactive adaptive and innate immunity, with evidence of
T-cell activation via the cytokines interleukin-2 (IL-2), IL-12,
IL-23 and IL-27.10 Some T-cell activation evidence undoubt-
edly emanates from tumor-infiltrating lymphocytes that tend to
be abundant in infected cancer tissues, yet are unable to control
growth of infected tumor cells.64 Other features of EBV-
positive cancers are (1) diminished glucocorticoid signaling,
suggesting an opportunity to test dexamethasone and other
immune modulators, (2) defective cell adhesion and (3) strong
caspase activity that might be exploited to tip the balance
towards death of infected cells.
When compared with non-malignant gastric mucosa,
EBV-positive cancers exhibit many of the same biochemical
features as uninfected cancers, including strong DNA damage
response pathways. A major difference is that interferon-γ
and IFN-γ-induced interferon regulatory factor-1 in the
IL-2-STAT4 pathway are overexpressed in EBV-positive
cancers versus uninfected cancers.65
EBV-RELATED RECEPTOR KINASE SIGNALING
Compared with non-malignant mucosa, TCGA investigators
reported that the two most marked features of EBV-positive
cancers are diminished hypoxia-inducible factor 1α-related
activity and diminished ERBB receptor signaling. These find-
ings raise the question of whether angiogenesis inhibitors or
ERBB family inhibitors might have differential efficacy in
infected vs uninfected cancers. Pending further studies, it seems
reasonable to continue to follow customary clinical
recommendations66 regarding use of drugs such as ramucir-
umab targeting vascular endothelial growth factor receptor-2
involved in angiogenesis67–69 or trastuzumab in the setting of
ERBB2 (HER2) overexpression/amplification.
EBV-positive cancers have evidence of activated BMP (bone
morphogenetic protein) signaling, implicating that the BMP/
SMAD pathway as a potential therapeutic target. In addition,
potentially druggable JAK2 or MET gene amplifications are
relatively frequent among EBV-positive cancers.7 Intriguing
Table 3 Methylated gene silencing in EBV-positive compared













RCOR2 0 NHLRC1 25
RHOF 1 TSPY26P 28
TMEM52 1 KIAA1383 29
CLDN3 1 ZNF530 32
HOXA10 1 KRT7 32
CRAT 3 ARHGEF10 32
FNDC4 4 PRDM5 42
PRKCDBP 4 THNSL2 42
BMP8B 6 RAB34 44
TXNRD3 7 CHST10 49
LDLRAD3 8 TP73-AS1 49
B3GALNT1 9 ZNF813 50
ESYT3 10 ZNF549 53
OSBP2 10 ZNF470 61
C2CD4B 12 ZNF518B 61
MAP1LC3A 12 HOXA1 63
C5orf42 14 LOC339803 64
SOGA1 14 PCDHGC5 64
SCRN1 16 TSPYL5 68
C8orf47 20 ZNF610 68
TPD52L1 22 ZFP28 70
ZNF542 76
Abbreviations: EBV, Epstein–Barr virus; TCGA, The Cancer Genome Atlas.
aEach gene was silenced in at least 95% of EBV-positive gastric cancers, as
reported by the TCGA Network.
Table 4 Strategies for virus-directed therapy
Enhance immune response to infected cells
‐Infuse virus-directed cytotoxic T cells
‐Upregulate viral antigen presentation
‐Activate T cells (e.g. PD-L1 inhibitor)
‐Reduce immune tolerance
Enhance immunogenicity of infected cells
‐Induce lytic viral gene expression
Reverse virus-mediated cell maintenance
‐Block viral drivers of growth, survival and immune evasion
‐Alter viral epigenetic controls (methylation, acetylation)
Trigger apoptosis of infected cells
‐The natural end point of lytic viral infection
‐Viral protein activates a toxin (gancyclovir)
Genomics of EBV-positive gastric cancer
ML Gulley
4
Experimental & Molecular Medicine
studies show EBV-positive gastric cancers preferentially over-
express CD274 and PDCD1LG2 (PD-L1 and PD-L2) as revealed
by RNAseq and by protein localization to malignant cells by
immunohistochemistry.10,70 Prior studies of lymphoma like-
wise revealed EBV-associated upregulation of CD274 on the
cell surface, which is IFN-γ-mediated, and thus inhibits killing
of infected cells by cytotoxic T cells expressing PD-1 ligand.71
Gain of four or more copies of the CD274 and PDC1LG2
genes, or mutation in the 3′-untranslated region of CD274, are
alternative mechanisms of overexpression.72 PDCD1LG2
thwarts T-helper type 2 T-cell function. Further work is needed
to explore virus-related immune evasion mechanisms, particu-
larly now that PD/PD-L inhibitor drugs are available.
Regardless of EBV status, most gastric cancers have at least
one aberrancy in a druggable pathway such as receptor tyrosine
kinase signaling.10,73–79 Newly identified in ‘genomically stable’
gastric cancers is activated RHOA singaling via mutation of
RHOA GTPase, or fusion events in RHOA inhibitors (ARH-
GAPs), broadening the opportunity to test inhibitors of the
RHOA effector ROCK that are well studied in vascular biology.
ROCK functions as a serine/threonine kinase impacting
CDH1-mediated cell adhesion, tumor microenvironment and
actin structural biology.10,80,81 CDH1, RHOA and ARHGAP
defects are common and are mutually exclusive. Hp infection
reportedly activates members of the RHO family of GTPases.
The CD44 gene is preferentially amplified in EBV-positive
cancers, and other commonly amplified or deleted genes are
listed in Table 6. Previously identified were a CD44 protein
variant or a CD44-SLC1A2 or SLC34A2-ROS1 fusion in cancer
tissues.82,83 Fusion genes are technically difficult to find by
next-generation sequencing, and expensive to identify by
fluorescence in situ hybridization. However, once identified
as a somatic variant, a fusion gene is considered to be a
particularly good tumor marker in that it tends to be quite
specific for neoplastic cells and is identifiable in ‘discarded’
next-generation sequencing reads that do not align to the
reference sequence using standard bioinformatic tools.84 Low-
level translocation detected by quantitative PCR could serve as
a marker of minimal residual disease.
EBV GENE EXPRESSION
Among 87 EBV-encoded mRNAs, 15 are highly expressed in
the majority of EBV-positive gastric cancers according to the
TCGA RNAseq data. Eight of these EBV transcripts (BARF0,
BALF3, BALF4, BALF5, A73, RPMS1, LF2 and LF1) are




















Figure 1 During latent infection, a very limited repertoire of viral gene is expressed. However, when an infected cell switches into the lytic
phase of active viral replication, dozens of viral proteins are expressed that trigger immune recognition and destruction. Cell death may be
enhanced by administering the anti-viral drug gancyclovir, a purine analog that is incorporated into DNA strands by DNA polymerase. Viral
thymidine kinase (BXLF1) and serine/threonine protein kinase/phosphotransferase (BGLF4) phosphorylate gancyclovir, which then stalls
DNA synthesis and triggers apoptosis. Intercellular transfer of phosphorylated gancyclovir can result in death of adjacent cells.
Table 5 Genes commonly mutated in gastric cancer
All molecular classesa
TP53 KRAS RNF43 RASA1
CDH1 MUC6 ABCA10 FAM46D
SMAD4 APC CTNNB1 PLB1
PIK3CA BCOR MACF1 CNGA4
RHOA EYA4 SMAD2 EIF2C4
ARID1A BNC2 SOHLH2 ERBB2 (HER2)
PTPRC
EBV-positive class vs EBV-negative classes
PIK3CA GRIK1 BCOR ARID1A
TCHH WNK1 MAMLD1
Abbreviation: EBV, Epstein–Barr virus.
aHypermutated cancers were excluded when compiling this list.
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the expressed viral miRs are also encoded.10,65,85 Although the
medical literature suggests that latent membrane protein 1 is
infrequently expressed in infected gastric adenocarcinoma by
protein assays, TCGA RNAseq revealed that both EBV latent
membrane protein encoding mRNAs (LMP1, LMP2A) were
consistently expressed, albeit at low level. Latent membrane
protein 2 or other viral gene products may contribute to
hypermethylated DNA that is characteristic of infected
cancers.86
Another interesting finding is consistent expression of
EBV BNLF2a, which acts to inhibit the transporter associated
with antigen processing, potentially thwarting antigen presen-
tation.87 Also consistently expressed is the BILF1 G-protein-
coupled receptor that downregulates human leukocyte antigen
class 1 protein expression.88 Both BNLF2a and BILF1 are thus
involved in the cellular evasion of immune destruction, and
are associated with the upregulation of the druggable natural
killer/T-cell inhibitor IDO1 (indoleamine 2,3-dioxygenase 1) in
EBV-positive tumors.65 As the IDO1 enzyme depletes trypto-
phan, it raises the question whether foods rich in tryptophan
could overcome the effect. A viral gene of uncertain function,
BNLF2b, is highly expressed, whereas EBNA1 and LF3 are
expressed consistently but at low levels. The remaining latent
and lytic viral genes (including the other EBNAs) are expressed
at very low levels or only in a fraction of tumors.10
Selected viral microRNAs (encoded in the viral BamH1A
region of the viral genome) were highly expressed in all
infected cancers in a fairly consistent pattern, according to
the TCGA microRNA sequencing data.10 The most highly
expressed of these EBV microRNAs are BART 10-5p, 7-3p
and 7-5p. Emerging data reveals their impact on gastric
carcinogenesis.89–91
EBV GENOME STRUCTURE AND A RARE
CHROMOSOMAL INTEGRATION EVENT
The EBV genome persists as an episome (double-stranded
DNA of almost 172 kb) inside latently infected cells, with
variable numbers of terminal repeat sequences within the
circularized viral genome serving as a marker of clonality.92
The presence of clonal viral DNA in EBV-positive gastric
cancers is evidence that infection precedes malignant transfor-
mation, a concept that is reinforced by histochemical evidence
of EBER expression in all neoplastic cells of a given patient, and
by evidence of EBV in some dysplastic lesions of the stomach
mucosa.93 Whether EBV infection of epithelial cells occurs
early or late during carcinogenesis is a subject of ongoing
investigation.94–96
Multiple viral polymorphisms have been reported,97–100 and
the extent to which these mutations in the EBV genome impact
gastric carcinogenesis is unknown. In the TCGA study, one
gastric cancer had evidence of integration of the EBV genome
into the human genome as revealed by multiple independent
RNAseq reads revealing a fusion transcript predicted to join the
first 20 amino acids of the human plasminogen receptor
(PLGRKT, alias C9orf46) to almost the entire coding sequence
of the early lytic EBV gene BHLF1 (alias EA-D). In this
particular tumor, BHLF1 was expressed but the remaining
viral gene expression pattern was not markedly different from
other infected tumors. It should be noted that PLGRKT is
located alongside JAK2, CD274 (PD-L1) and PDCD1LG2
(PD-L2) within the 9p24.1 locus that is commonly amplified
in EBV-positive gastric cancers. Overall, the findings imply that
viral integration can occur, is rare event or else does not does
not frequently result in fusion transcripts, and may contribute
to the activation of known oncogenes.
HISTOPATHOLOGY OF EBV-POSITIVE GASTRIC
ADENOCARCINOMA TISSUES
Prior work has shown that carcinoma with lymphoid stroma is
characteristic of many EBV-positive cancers, although some
infected cancers have more conventional tubular (intestinal)
appearance by microscopy. Histologic classification of cancers
using Lauren or World Health Organization schemes reveals
that ‘genomically stable’ cancers are enriched for diffuse
histology10 (see Table 7). Further work should delve into
histologic features differentiating the four molecular classes
such as the character of lymphoid stroma and epithelial cell
cytology/architecture (e.g. signet ring cell type, solid type vs
isolated cell diffuse architecture as distinguished by Carneiro
et al.101).
In EBV-positive cancers, the EBV genome is localized within
the nucleus of malignant cells and is propagated to daughter
cells during cell division. EBER in situ hybridization is
considered the gold standard assay for assigning a tumor as
‘EBV-positive’ by virtue of localization of abundantly expressed
EBER1 or EBER2 long noncoding RNAs to malignant cells.92
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Abbreviation: EBV, Epstein–Barr virus.
aProposed oncogenes and tumor suppressor genes are shown in bold.
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High levels of EBV DNA (using quantitative PCR) or encoded
viral RNA (using microarray, RNAseq or microRNA sequen-
cing) are surrogate methods to distinguish EBV-positive
cancers from EBV-negative cancers.1,10,102 High levels of EBV
DNA are also seen during active viral infection (e.g. infectious
mononucleosis, chronic active EBV infection, oral hairy
leukoplakia), whereas low-level infection is commonly present
in adult humans who were previously infected and then carry
the virus for life in a small proportion of B lymphocytes.92
CLINICOPATHOLOGIC FEATURES IMPACTING
TREATMENT
From a clinical management perspective, it is clear that factors
independent of molecular class impact treatment decisions at
this time. Tumor stage is critical for devising plans for surgical
resection, radiation and chemotherapy. ERBB2 (HER2) gene
amplification qualifies metastatic cancer patients for HER2-
directed antibody therapy.103 Yet, tumor stage, ERBB2 status
and survival were not strongly linked with molecular class,10
emphasizing that molecular class represents a conceptual
biologic framework more than a practical tool at this time.
Much remains to be learned about what appears to be four
major routes of disease pathogenesis, and to capitalize on that
understanding for purposes of diagnosis, management and
prevention of cancer. Meanwhile, as most cancers have somatic
variants in biochemical pathways that are putative targets for
existing drugs, design of clinical trials is warranted to test the
efficacy of targeted therapies.
IMPLICATIONS FOR SURGICAL PATHOLOGISTS AND
MOLECULAR PATHOLOGISTS
The reason why pathologists classify cancers is to promote
clinical decision-making that improves patient outcomes.
Classification criteria are periodically revised to incorporate
new scientific evidence and methods of analysis. At this time,
assignment to one of four molecular classes does not appear to
add value beyond the features already actionable for clinical
decision-making in gastric tumors (e.g. carcinoma vs gastro-
intestinal stromal tumor, ERBB2 (HER2) gene amplification in
metastatic carcinoma, stage). Nevertheless, microscopic and
ancillary tools can certainly be validated and applied to
distinguish the four molecular subtypes at a reasonable cost,
making it feasible to retrospectively and prospectively test
clinical trial cohorts for molecular class.
The GastroGenus Gastric Cancer Classifier is a genomic
assay that tests for EBV positivity,MLH1 promoter methylation
and sequences of selected cancer genes in the context of
histopathologic classification. Results of the test in paraffin-
embedded tumor tissue are interpreted with respect to
molecular class and to find actionable gene variants in patients
who fail standard therapy.104 Although therapy options for
metastatic cancer patients remain limited and largely
Table 7 Histopathologic characteristics of the four molecular classes of gastric adenocarcinomaa










Female 113 38 4 32 44 20
Male 182 62 12 15 53 20
Lauren classification
Diffuse 69 23 7 9 26 58
Intestinal 196 66 8 25 60 8
Mixed 19 6 16 16 53 16
Not specified 11 4 27 64 9 0
WHO classification
Mixed 19 6 16 16 53 16
Mucinous 18 6 0 39 50 11
Papillary 22 8 5 18 68 9
Poor cohesive 69 23 7 9 26 58
Tubular 140 48 6 25 62 6
Not specified 27 9 30 33 30 7
Anatomic site
Antrum 114 39 5 27 43 25
Body 116 39 14 22 49 16
Proximal 57 19 7 9 65 19
Not specified 8 3 0 38 50 13
Abbreviations: TCGA, The Cancer Genome Atlas; WHO, World Health Organization.
aData from the TCGA Network.
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palliative,103 clinicians and patients increasingly demand geno-
mic data by which to evaluate options for clinical trial
enrollment, the results of which are likely to enhance under-
standing of pathogenesis and define the role of clinicopatho-
logic tests in predicting drug efficacy.
Localization of EBV to malignant cells by EBER in situ
hybridization remains the gold standard for assigning the EBV-
positive class of cancers.92 EBV-positive gastric cancer patients
qualify for enrollment in clinical trials of EBV-directed therapy
(e.g. NCT00982449, NCT02080416). These trials use lytic
induction therapy to convert infected cells from latent to
replicative phases of viral infection, which is hypothesized to
trigger cell death with potential for bystander killing of adjacent
cells.35,48
Also available are multiple trials of targeted therapy for
gastric cancer having a particular gene defect or gene expres-
sion status. Among these trials are dozens for ERRB2 (HER2)
gene defects (e.g. NCT01602406); NCT01613950 for PIK3CA
mutation; NCT02016534 or NCT01874938 for MET gene
amplification, NCT02052778 for FGF or FGFR gene defects;
NCT02187783 for CDK4, CDK6, CCND1, CCND3 or
CDKN2A defects; NCT02022982 for KRAS mutation; and
NCT01522820 for CTAG1B or CTAG2 expression.
It is likely that the MSI molecular class of gastric cancers can
be identified by virtue of MSI-high status (which requires
testing of both tumor and germline DNA) or by MLH1
hypermethylation testing that requires only tumor tissue.
Heretofore, MSI status has not generally been evaluated in
gastric cancer patients except in the rare instance of suspected
Lynch syndrome (e.g. personal or family history of pertinent
cancer types, young age at diagnosis, blood relative with Lynch
syndrome). The MSI test is used primarily to identify evidence
of DNA mismatch repair defects in colorectal or endometrial
cancer patients as part of Lynch syndrome screening.105 With
the advent of massive parallel sequencing panels to identify
germline variants in mismatch repair genes, it is likely that the
MSI test will eventually be replaced by more cost-effective and
direct means of testing for heritable cancer risk.106–108 For
purposes of assigning molecular class of gastric cancer, MLH1
methylation testing is likely to be a suitable surrogate test.
A treatment trial of PD-1 antibody therapy (pembrolizumab,
NCT01876511) currently enrolls patients with ‘MSI-positive’
gastric cancer. Methylation-related silencing of MLH1
undoubtedly contributes to defective DNA repair and accu-
mulating mutations in cancer tissue. MLH1 promoter methyla-
tion also suggests better response to fluorouracil chemotherapy.
HERITABLE PREDISPOSITION TO GASTRIC CANCER
Familial predisposition to gastric cancer is being examined
in a clinical trial of subjects from high-risk families
(NCT00172861). Pertinent hereditary cancer syndromes
include Peutz-Jeghers (STK11), Li-Fraumeni (TP53), Lynch
(MLH1,MSH2,MSH6, PMS2, EPCAM,MUTYH) and Cowden
(PTEN) syndromes, as well as hereditary diffuse gastric cancer
(CDH1).109 In the latter disorder, a hypomethylating drug is
being considered to prevent cancer progression from prema-
lignant lesions by thwarting CDH1 promoter methylation.
Table 8 lists genes reportedly associated with gastric cancer
predisposition, some of which encode immune response factors
that defend against EBV, Hp and other pathogens.
CLINICAL IMPLEMENTATION OF GENOMIC SERVICES
Well-validated genomic tests can provide robust, accurate and
reproducible results that are powerful by virtue of the number
of analytes that are evaluated, redundancy that boosts con-
fidence in results, cross-species flexibility to detect pathogen-
related human disease and a growing evidence base linking
genetic findings to disease status in a manner that promotes
favorable patient outcomes. Genomic tests typically analyze
dozens to billions of targets in a single assay using microarrays
or massive parallel sequencing. Performance studies of mole-
cular technology have shown that genomic profiles of DNA,
mRNA, methylation status and noncoding RNA can be
rendered analytically sound and clinically informative for
medical decision-making in clinical trials and ultimately in
routine patient care.110–116
Building on decades of well-honed principles of laboratory
medicine, pathologists and other laboratory professionals
provide genomic services in clinical settings.111 Implementation
is supported by (1) reliable commercial sources of reagents,
supplies, instruments and software; (2) advances in biospeci-
men science promoting integrity of the nucleic acids input to
the assays;117 (3) novel quality control reagents and methods to
judge assay performance;111,118 (4) informatics to facilitate
interpretation of complex data generated from assays of patient
and control specimens; (5) evidence of analytic and clinical
performance; and (6) justification that the assay adds value (e.g.
is faster, cheaper or more informative) than current means of
diagnosis, monitoring, preventing or predicting efficacy of a
given intervention in the pertinent population.
Each testing laboratory has a ‘standard operating procedure’
that, along with a ‘validation report’, establishes the evidence
base substantiating indications for testing, specimen collection
and processing, step-by-step analysis, quality control processes
and guidance for interpreting data and for generating a report
to the patient’s medical record.119 Analytic interpretation is the
process by which raw data is converted into reportable results.
Clinical interpretation is the process by which a pathologist or
Table 8 Genes reportedly associated with heritable
predisposition to gastric cancer
APC CDH1 FASLG IL6 MUC2 PRKAA1 TLR1
ATM CHEK2 GSTM1 IL8 MUTYH PSCA TLR2
GJA4 CTNNA1 GSTP1 LEPR NOS2 PTEN TLR4
MSH6 CTNNB1 GSTT1 LTA NQO1 PTGS2 TLR9
APC CYP2E1 IFNGR1 MET PARP1 PTPN11 TNF
APOE DNMT3A IL10 MIF PLCE1 SMAD4 TP53
BIRC5 EPCAM IL17A MLH1 PMS2 SOD2 TYMS
BMPR1A ERCC1 IL1B MSH2, POLD1 SPP1 VEGFA
BRCA1 ERCC5 IL1RN MTHFR POLE STK11 WWOX
BRCA2 FAS IL4R MUC1 PPARG TGFB XRCC1
Genomics of EBV-positive gastric cancer
ML Gulley
8
Experimental & Molecular Medicine
other laboratory professional judges the medical significance of
results in light of the clinical indication for which the service
was ordered, the findings and the intended use of test results.
Analytic interpretation relies on thorough understanding of
the technical strengths and weaknesses of the test system based
on prior experience gathered during validation studies, litera-
ture review and subsequent clinical practice. Owing to test
complexity and the need to interpret results in the context of
the many quality assurance measures that are in place (includ-
ing, in the case of molecular oncology specimens, histopatho-
logic evaluation of the input lesion), it is clear that the resulting
genomic sequence is not a stand-alone feature but rather a
component of a package of technical and professional work
constituting a medical service.
Interpretation is impacted by the level of confidence in
results, as revealed by redundant findings (e.g. depth of
coverage, mutant allele frequency, multiple tests of the same
analyte or pathway, presence of both 5′ and 3′ ends of an
mRNA) and the outcome of controls and quality checks (e.g.
endogenous controls to evaluate adequacy of patient nucleic
acid for the intended use, exogenous and spiked controls to
evaluate run- and specimen-specific performance of the test
system). Medical judgment is required to interpret findings in
light of correlative clinical information (e.g. age, gender, tumor
stage, histologic and immunohistochemical findings), pub-
lished literature, validation work, genotype/phenotype data-
bases and other reliable sources. Importantly, the interpretation
must address the medical question posed by the ordering
physician, and also consider incidental findings of importance
to the patient and their blood relatives.
The report submitted to the patient’s medical record
documents findings and provides guidance to support clinical
decision-making and follow-up. Such a report is best generated
by a laboratory physician who is expert in disease pathobiology
and in molecular technology, and who takes responsibility for
the analyses and for the quality control processes supporting
their interpretation.
In high complexity clinical laboratories in the United States
(and in laboratories worldwide that are accredited by the
College of American Pathologists or that meet equivalent
standards), a laboratory physician must be available to discuss
medical indications for testing and clinical implications of test
results in a given patient. Published guidance outlines the
principles of clinical grade genomic assay development, imple-
mentation and maintenance.119–123
SUMMARY
This article describes recent advances in understanding gastric
carcinogenesis. The findings imply that gastric adenocarcinoma
is four separate diseases with respect to molecular pathogenesis.
Prior epidemiologic studies may have overlooked the EBV
molecular class that comprises only 9% of cancers, while
emphasizing the chromosome instability class that comprises
50% of cancers. Furthermore, historic studies lumped cases
with CpG island hypermethylation into a single group, but
emerging evidence reveals the distinct patterns of
hypermethylation in EBV-positive vs MSI molecular classes of
cancer. Cancers of diffuse histology tend to be ‘genomically
stable’ implying few mutations or gene amplifications, and
prevalent defects in RHO signaling downstream of G-protein-
coupled receptors.
Pathologists increasingly have the tools to support clinical
trials of targeted therapy and to advance routine health care
using ancillary molecular tests. The ‘GastroGenus Gastric
Cancer Classifier’ is an example of a genomic test panel that
adds value beyond histopathology of formalin-fixed cancer
tissue by evaluating EBV status, MLH1 promoter methylation
and multiple cancer gene sequences to interpret molecular class
and to identify actionable mutations revealing clinical trial
options or off-label use of an existing drug for metastatic
cancer patients who fail standard therapy. On the horizon is
integrative genomic technology combining gene expression
profiles with DNA/RNA sequence information such as muta-
tion, splice variants, fusion and pathogen identification.
Advanced genomic technology shows promise to assist in early
diagnosis, classification and monitoring of affected patients.
Hopefully cancer prevention is also among the ways that
genomic technology might improve public health.
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